低蛋白饮食及其在SGLT2抑制剂时代的协同作用
Jason Patel1, Kamyar Kalantar-Zadeh2, Shivam Joshi3
1University of Arizona College of Medicine - Phoenix, Phoenix, AZ.
Advances in kidney disease and health
|March 7, 2024
概括
低蛋白饮食 (LPD) 通过减少蛋白质和改善功能,有利于慢性病 (CKD). 将LPD与SGLT2抑制剂等药物结合使用可能为更好的CKD管理提供协同效应.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 饮食科学 饮食科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 低蛋白饮食 (LPD) 是慢性病 (CKD) 的确立干预措施,通常为0.60.8g/kg/day.
- 通过降低球压力和尿素生成,LPD可以改善损伤,减少蛋白尿,并延迟透析.
- 植物主导的LPD通过蛋白质质量提供额外的脏保护.
研究的目的:
- 审查LPD在CKD管理中的作用.
- 探索LPD与药理学药物的协同效应,包括SGLT2抑制剂.
主要方法:
- 对LPD和CKD现有研究的文献综述.
- 对LPD和相关药物的作用机制的分析.
- 综合关于综合治疗方法的证据.
主要成果:
- 腰部肺部疾病降低了球压力和尿素生成,有利于慢性病患者.
- -葡萄糖共运输体2 (SGLT2) 抑制剂有效降低结核病中的白蛋白尿和缓慢的GFR下降.
- 预计LPD与SGLT2抑制剂和其他疗法相结合时会产生附加效应.
结论:
- 量身定制的LPD对于管理各种CKD类型至关重要,即使有医疗治疗.
- 结合LPD与SGLT2抑制剂或其他药理学药物的结合有望改善CKD管理.
- 对联合治疗策略的进一步研究是有必要的.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
186
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
186
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
175
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
175
Secondary Active Transport
7.0K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.0K
Glucose Absorption Into the Small Intestine
31.6K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.6K


